Cyberounds Logo
January 18, 2020 | LOGIN | REGISTER | HELP | 
email a friend print Bookmark and Share
New Therapies for Rheumatoid Arthritis
CME credit is no longer available for this conference.
Chaim Putterman, M.D., and Peter Barland, M.D.

Dr. Putterman is Assistant Professor of Medicine at the Albert Einstein College of Medicine and the Director of the Arthritis Clinic at Montefiore Medical Center. Drs. Putterman and Barland report no commercial conflicts of interest.

Release Date: 10/01/2002
Termination Date: 10/01/2005

Estimated time to complete: 1 hour(s).

Albert Einstein College of Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Albert Einstein College of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Learning Objectives
Upon completion of this Cyberounds®, you should be able to:
  • Describe the role of TNF and IL-1b in the pathogenesis of rheumatoid arthritis
  • Discuss the mechanism of action, dosing, major side effects and indications for the use of leflunomide, infliximab, etanercept and anakinra in rheumatoid arthritis
  • Enumerate the differences between infliximab and etanercept
  • Discuss the potential effects of biologic agents on structural damage to cartilage and bone in rheumatoid joints.

This conference may include discussion of commercial products and services.

The opinions expressed herein are those of the authors and do not necessarily represent the views of the sponsor or its publisher. Please review complete prescribing information of specific drugs or combination of drugs, including indications, contraindications, warnings and adverse effects before administering pharmacologic therapy to patients.
Please click below to accept the terms of this CME activity